Sleep Disorders

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

The executive vice president of research and development at Jazz Pharmaceuticals discussed what the clinical community needs to know ahead of the regulatory decision on JZP-258 in the treatment of cataplexy and excessive daytime sleepiness in narcolepsy.

New data suggest that brain changes in the posterior cingulate cortex and precuneus as a result of SDB may increase the risk of Alzheimer disease, supporting prior findings which imply a link between the conditions.

Pear Therapeutics’ Somryst intervention provides tailored neurobehavioral interventions intended to improve the symptoms of insomnia, via cognitive behavioral therapy and algorithm-driven sleep restriction.

The novel oxybate agent is seeking an indication for the treatment of cataplexy and excessive daytime sleepiness in those 7 years and older with narcolepsy. The PDUFA date is July 21, 2020.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed the comorbidities related to narcolepsy.

The webinar, a partnership between Women Neurologist's Group (WNG) and NeurologyLive, features the latest updates from CMS on billing and coding for telemedicine visits.

Telemedicine has potential to play a key role in diagnosis and testing during the outbreak of COVID-19

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine discussed the daily challenges patients with narcolepsy face.

A proof‐of‐concept assessment showed that women with chronic migraine and insomnia can be reasonably treated with digital cognitive behavioral therapy for insomnia, with data suggesting it may improve both conditions.

The director of the Sleep Clinic at Boston Children’s Hospital discussed the lack of clinical research for pediatric sleep disorders and what the current landscape looks like.

The director of the Sleep Clinic at Boston Children’s Hospital discussed the sleep disorders she sees in her practice, and how she and her colleagues best address these pediatric patients.

Impaired rhythm production and perception in patients with idiopathic REM sleep behavior disorder are correlated with early markers of Parkinson disease, according to study results.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.

Following the 2011 guideline development process, this 2020 guideline focused on addressing a number of types of sleep disturbance in children and adolescents with autism spectrum disorder.

New Medicare data has suggested that those with undiagnosed obstructive sleep apnea have higher annual health care costs than their counterparts, with this high economic burden accompanying already impacted function and quality of life.

The drug was previously indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

New data has suggested that although adherence rates for CPAP for patients with OSA are lower than ideal, the benefits patients receive from its use can still be significant.

Using the Sleepio intervention resulted in significantly greater improvement in insomnia symptoms, as well as almost all other outcomes assessed, in women who were pregnant with insomnia.

Neurology News Network for the week ending January 27, 2020.

The novel oxybate agent has been submitted as an investigational treatment for cataplexy and excessive daytime sleepiness in those ages 7 years and older with narcolepsy.

The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.

Neurology News Network for the week ending January 11, 2020.

The drug was associated with significant improvements in sleep onset, sleep efficiency, and wake-after-sleep onset for both doses compared with placebo.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Karl Doghramji, MD, medical director of the Jefferson Sleep Disorders Center, reviews optimal management strategies for elderly patients with insomnia disorder.

The small-molecule dual orexin receptor antagonist was approved based on data from 2 pivotal phase 3 studies which showed statistical superiority over placebo for sleep onset latency.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.